Reproducibilidad de la densidad vascular peripapilar, cabeza del nervio óptico y área macular por OCT-A de acuerdo con la severidad del glaucoma / Reproducibility of peripapillary, optic nerve head and macular vessel density by OCT-A according to glaucoma severity staging

Objetivo Evaluar la reproducibilidad de la densidad vascular (DV) peripapilar, cabeza del nervio óptico (ONH-PP) y área macular mediante angiografía por tomografía de coherencia óptica de dominio espectral (SD OCT-A) en pacientes con glaucoma y en sujetos sanos. Métodos Estudio transversal que evaluó 63 ojos de 63 sujetos, incluyendo 33 pacientes con glaucoma y 30 sujetos sanos. El glaucoma se clasificó en leve, moderado o avanzado. Dos exploraciones consecutivas fueron adquiridas por Spectralis Module OCT-A (Heidelberg, Alemania) y proporcionaron imágenes del complejo vascular superficial (SVC), del plexo vascular de la capa de fibra nerviosa (NFLVP) y del plexo vascular superficial (SVP); del complejo vascular profundo (DVC), del plexo capilar intermedio (ICP) y del plexo capilar profundo (DCP). La DV (%) fue calculada mediante AngioTool. Se calcularon los coeficientes de correlación intraclase (ICC) y los coeficientes de variación (CV). Resultados Respecto a la DV de ONH-PP, el mejor ICC lo presentó el glaucoma avanzado (0,86-0,96) y moderado (0,83-0,97) en comparación con el glaucoma leve (0,64-0,86). Para la DV macular, los resultados de ICC para las capas retinianas superficiales fueron mejores para el glaucoma leve (0,94-0,96), seguido por el glaucoma moderado (0,88-0,93) y por el avanzado (0,85-0,91), y para las capas retinianas más profundas el ICC fue más alto para el glaucoma moderado (0,95-0,96), seguido por el glaucoma avanzado (0,80-0,86) y por el leve (0,74-0,91). Los CV oscilaron entre el 2,2% y el 10,94%. Entre los sujetos sanos, los ICC para las mediciones de DV ONH-PP (0,91-0,99) y para las mediciones de la DV macular (0,93-0,97) fueron excelentes en todas las capas, con CV del 1,65% al 10,33% (AU)

Objective To assess the reproducibility of peripapillary, optic nerve head (ONH-PP) and macular vessel density (VD) by spectral domain optical coherence tomography angiography (SD OCT-A) in glaucoma patients and healthy subjects. Methods Cross-sectional study assessing 63 eyes of 63 subjects, including 33 glaucoma patients and 30 healthy subjects. Glaucoma was classified in mild, moderate, or advanced. Two consecutive scans were acquired by spectralis module OCT-A (Heidelberg, Germany), and provided images of the superficial vascular complex (SVC), nerve fiber layer vascular plexus (NFLVP), superficial vascular plexus (SVP), deep vascular complex (DVC), intermediate capillary plexus (ICP) and deep capillary plexus (DCP). VD (%) was calculated by AngioTool. Intraclass correlation coefficients (ICCs) and coefficients of variation (CV) were calculated. Results Among ONH-PP VD, better ICC presented advanced (0.86-0.96) and moderate glaucoma (0.83-0.97) compared with mild glaucoma (0.64-0.86). For the macular VD reproducibility, ICC results for superficial retinal layers were better for mild glaucoma (0.94-0.96) followed by moderated (0.88-0.93) and advanced glaucoma (0.85-0.91), and for deeper retinal layers ICC was better for moderate glaucoma (0,95-0,96) followed by advanced (0.80-0.86) and mild glaucoma (0.74-0.91). CVs ranged from 2.2%% to 10.94%. Among healthy subjects, ICCs for the ONH-PP VD measurements (0.91-0.99) and for the macular VD measurements (0.93-0.97) were excellent in all layers, with CVs from 1.65% to 10.33%. Conclusions SD OCT-A used to quantify macular and ONH-PP VD showed excellent and good reproducibility in most layers of the retina, both in healthy subjects and in glaucoma patients regardless of the severity of the disease (AU)

Reproducibility of peripapillary, optic nerve head and macular vessel density by OCT-A according to glaucoma severity staging.

OBJECTIVE: To assess the reproducibility of peripapillary, optic nerve head (PP-ONH) and macular vessel density (VD) by Spectral Domain optical coherence tomography angiography (SD OCT-A) in glaucoma patients and healthy subjects. METHODS: Cross-sectional study assessing 63 eyes of 63 subjects, including 33 glaucoma patients and 30 healthy subjects. Glaucoma was classified in mild, moderate, or advanced. Two consecutive scans were acquired by Spectralis Module OCT-A (Heidelberg, Germany), and provided images of the superficial vascular complex (SVC), nerve fiber layer vascular plexus (NFLVP), superficial vascular plexus (SVP); deep vascular complex (DVC), intermediate capillary plexus (ICP) and deep capillary plexus (DCP). VD (%) was calculated by AngioTool. Intraclass correlation coefficients (ICCs) and coefficients of variation (CV) were calculated. RESULTS: Among PP-ONH VD, better ICC presented advanced (ICC 0.86-0.96) and moderate glaucoma (ICC 0.83-0.97) compared with mild glaucoma (0.64-0.86). For the macular VD reproducibility, ICC results for superficial retinal layers were better for mild glaucoma (0.94-0.96) followed by moderated (0.88-0.93) and advanced glaucoma (0.85-0.91), and for deeper retinal layers ICC was better for moderate glaucoma (0.95-0.96) followed by advanced (0.80-0.86) and mild glaucoma (0.74-0.91). CVs ranged from 2.2% to 10.94%. Among healthy subjects, ICCs for the PP-ONH VD measurements (0.91-0.99) and for the macular VD measurements (0.93-0.97) were excellent in all layers, with CVs from 1.65% to 10.33%. CONCLUSIONS: SD OCT-A used to quantify macular and PP-ONH VD showed excellent and good reproducibility in most layers of the retina, both in healthy subjects and in glaucoma patients regardless of the severity of the disease.

Peripapillary and optic nerve head vessel density of glaucoma and healthy subjects from Afro-Caribbean and European descent: A pilot study.

PURPOSE: To compare the peripapillary and optic nerve head vessel density (PP-ONH VD) between glaucoma patients (all, early, moderated, and advanced) and healthy subjects of Afro-Caribbean descent (AD) and European descent (ED). METHODS: This was a cross-sectional study. One eye was evaluated in 90 subjects, including 66 glaucoma patients and 24 healthy subjects, who underwent PP-ONH VD imaging using SPECTRALIS® Optical Coherence Tomography Angiography (OCT-A). We analysed the superficial vascular complex using the AngioTool version 0.6a software. The correlation between the PP-ONH VD and visual field mean deviation (MD) was evaluated using a scatter plot and Spearman's rho correlation coefficient. RESULTS: Among the healthy subjects, the AD group had a lower superficial PP-ONH VD [43.29±3.25% (mean±standard deviation)] than the ED group (46.06±1.75%) (P=0.016). Overall, superficial PP-ONH VD did not show any significant differences between the total AD and ED glaucoma patients or in the subgroup analyses (early/moderate/advanced) (AD: 32.73±6.70%, 37.11±5.72%, 32.48±5.73%, 27.76±4.74%, respectively; ED: 33.94±6.89%, 38.52±3.82%, 35.56±4.18%; 27.65±6.31%, respectively) (P>0.05 for all). A strong, statistically significant correlation was established between vessel density and mean deviation among AD and ED glaucoma patients (r=0.709 and r=0.704, respectively) (P<0.001 for both). CONCLUSION: This pilot study shows that healthy subjects of AD had lower peripapillary and optic nerve head superficial vessel density than healthy subjects of ED, but no significant differences were found between AD and ED glaucoma groups (all, early, moderate, or advanced).

Manejo de las úlceras corneales neurotróficas con Cacicol®- ReGeneraTing Agent: serie de casos / Management of corneal neurotrophic ulcers with Cacicol®-RGTA (ReGeneraTing Agent): a case series

OBJETIVO: Las úlceras corneales neurotróficas son difíciles de tratar y las terapias convencionales fracasan con frecuencia. Un nuevo agente regenerativo de la matriz extracelular («ReGeneraTing Agents»), Cacicol® (Laboratoires Théa), ha demostrado buenos resultados en los últimos años. El objetivo de este estudio fue evaluar la respuesta a Cacicol® en una serie de casos con úlceras corneales neurotróficas. MÉTODOS: Serie de casos retrospectiva. Once pacientes con úlceras corneales neurotróficas que no respondieron a una terapia convencional fueron tratados con Cacicol®. Un ciclo incluyó una gota cada 2 días durante 5 días. RESULTADOS: El rango de duración de la terapia convencional, previa al comienzo del tratamiento con Cacicol® fue 0 a 91 días. Tras introducir Cacicol® el 82% (9/11) de los casos se curaron y el 18% (2/11) no lo hicieron, llegando a requerir un trasplante de membrana amniótica o una queratoplastia penetrante, respectivamente. El 67% (6/9) de los pacientes curados requirieron solo un ciclo de Cacicol® y el 45% (5/11) pacientes necesitaron más de un ciclo. Un caso de úlcera corneal bacteriana respondió favorablemente pero un caso infectado por Acanthamoeba fracasó. En la mayoría de los pacientes, la agudeza visual mejoró o se mantuvo. CONCLUSIÓN: Cacicol® resultó una terapia exitosa en una alta proporción de úlceras neurotróficas, incluidas las infecciosas. Algunos casos requieren más de un ciclo de Cacicol® o su uso como primer línea de tratamiento

PURPOSE: Neurotrophic corneal ulcers are difficult to treat, and the conventional treatment often results in failure. A new matrix regenerating agent ("ReGeneraTing Agents"), Cacicol® (Laboratoires Théa), has demonstrated good results over the last few years. Therefore, the aim of this study was to evaluate the response to Cacicol® in a series of cases with neurotrophic corneal ulcers. METHODS: Retrospective case series looking at 11 patients with corneal ulcers unresponsive to conventional therapy that underwent treatment with Cacicol®. One cycle included 1 drop every two days for 5 days. RESULTS: The range of conventional therapy prior to Cacicol® was 0-91 days. On introducing Cacicol® 82% (9/11) of the cases were cured, and 18% (2/11) failed, requiring an amniotic membrane transplant or penetrating keratoplasty. The healing only required one cycle of Cacicol® in 67% (6/9) of the patients. More than one cycle of Cacicol® was needed in 45% (5/11) patients. One corneal bacterial ulcer responded favourably and one case related to Acanthamoeba did not respond. Most of the patients improved or maintained their visual acuity. CONCLUSION: Cacicol® was a useful therapy in a high number of difficult neurotrophic corneal ulcers, including corneal infections. Some cases may require more than one cycle of Cacicol® or used as first-line treatment in order to achieve the desired result

Management of corneal neurotrophic ulcers with Cacicol®-RGTA (ReGeneraTing Agent): a case series. / Manejo de las úlceras corneales neurotróficas con Cacicol®- ReGeneraTing Agent: serie de casos.

PURPOSE: Neurotrophic corneal ulcers are difficult to treat, and the conventional treatment often results in failure. A new matrix regenerating agent ("ReGeneraTing Agents"), Cacicol® (Laboratoires Théa), has demonstrated good results over the last few years. Therefore, the aim of this study was to evaluate the response to Cacicol® in a series of cases with neurotrophic corneal ulcers. METHODS: Retrospective case series looking at 11 patients with corneal ulcers unresponsive to conventional therapy that underwent treatment with Cacicol®. One cycle included 1 drop every two days for 5 days. RESULTS: The range of conventional therapy prior to Cacicol® was 0-91 days. On introducing Cacicol® 82% (9/11) of the cases were cured, and 18% (2/11) failed, requiring an amniotic membrane transplant or penetrating keratoplasty. The healing only required one cycle of Cacicol® in 67% (6/9) of the patients. More than one cycle of Cacicol® was needed in 45% (5/11) patients. One corneal bacterial ulcer responded favourably and one case related to Acanthamoeba did not respond. Most of the patients improved or maintained their visual acuity. CONCLUSION: Cacicol® was a useful therapy in a high number of difficult neurotrophic corneal ulcers, including corneal infections. Some cases may require more than one cycle of Cacicol® or used as first-line treatment in order to achieve the desired result.

Hemorragia vítrea una rara manifestación del hamartoma astrocítico retiniano: a propósito de un caso pediátrico / Vitreous haemorrhage a rare manifestation of retinal astrocytic hamartoma: a paediatric case report

Introducción: El hamartoma astrocítico retiniano es un tumor benigno generalmente asintomático, asociado o no al complejo de esclerosis tuberosa. La hemorragia vítrea es una rara presentación. Caso clínico: Paciente de 12 años acude por visión de "una mancha negra" en el hemicampo temporal superior del ojo derecho. Refiere un episodio similar hace 2 años. En lámpara de hendidura el polo anterior es normal. En la funduscopia se evidencia una masa de aspecto translúcido blanco-amarillenta peripapilar y hemorragia vítrea peripapilar. Las características de la autofluorescencia, angiografía fluoresceínica y la tomografía de coherencia óptica son compatibles con un hamartoma astrocítico retiniano. Los estudios complementarios (serología y radiografías) y examen clínico completo descartan afectación sistémica asociada. Se procedió a un seguimiento estrecho del paciente hasta reabsorción de la hemorragía vítrea. Conclusión: La hemorragia vítrea es una rara complicación de hamartoma astrocítico retiniano y dificulta la exploración fundoscópica. Debería descartarse afectación sistémica

Introduction: Retinal astrocytic hamartoma is generally an asymptomatic benign tumour that may or may not be associated with the tuberous sclerosis complex. Haemorrhage is a rare presentation. Case report: The case concerns a 12-year-old patient with "a black spot" vision in the upper temporal hemifield of the right eye, who referred a similar episode 2 years ago. The anterior pole was normal in the slit lamp. A mass of translucent white-yellow peri-papillary appearance and vitreous peri-papillary haemorrhage was observed in funduscopy. The autofluorescence, fluorescence angiography, and optical coherence tomography characteristics were all compatible with retinal astrocytic hamartoma. Complementary studies (serology and X-rays) and the complete clinical examination rule out associated systemic involvement. The patient was followed-up closely until the vitreous haemorrhage was reabsorbed. Conclusion: Vitreous haemorrhage is a rare complication of Retinal astrocytic hamartoma and funduscopic exploration is difficult. Systemic involvement should be ruled out

Vitreous haemorrhage a rare manifestation of retinal astrocytic hamartoma: a paediatric case report. / Hemorragia vítrea una rara manifestación del hamartoma astrocítico retiniano: a propósito de un caso pediátrico.

INTRODUCTION: Retinal astrocytic hamartoma is generally an asymptomatic benign tumour that may or may not be associated with the tuberous sclerosis complex. Haemorrhage is a rare presentation. CASE REPORT: The case concerns a 12-year-old patient with "a black spot" vision in the upper temporal hemifield of the right eye, who referred a similar episode 2 years ago. The anterior pole was normal in the slit lamp. A mass of translucent white-yellow peri-papillary appearance and vitreous peri-papillary haemorrhage was observed in funduscopy. The autofluorescence, fluorescence angiography, and optical coherence tomography characteristics were all compatible with retinal astrocytic hamartoma. Complementary studies (serology and X-rays) and the complete clinical examination rule out associated systemic involvement. The patient was followed-up closely until the vitreous haemorrhage was reabsorbed. CONCLUSION: Vitreous haemorrhage is a rare complication of Retinal astrocytic hamartoma and funduscopic exploration is difficult. Systemic involvement should be ruled out.

Historia del tracoma / History of tracoma

No disponible